EST Cathie Wood’s ARK Investment bought 176K shares of Crispr Therapeutics (CRSP) todayDon't Miss our Black Friday Offers:Discover the ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

NOVEL molecular regulators of rheumatoid arthritis (RA) inflammation were presented as part of a plenary abstract session at ...

Rather than training the algorithm on content scraped from the internet, scientists trained the AI on nearly three million genomes.

The College of Idaho is thrilled to celebrate the incredible achievements of our students and faculty who showcased their groundbreaking research at the 2024 Murdock College Science Research ...

The Thanksgiving pull has arrived, and produce markets have more than a few things to be grateful for, says ProduceIQ.

As BridgeBio approaches its FDA target date for approval of TTR stabilizer acoramidis to treat the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM), the company has presented more ...

A virologist named Beata Halassy recently made headlines after publishing a report of successfully treating her own breast ...

Evo marks the next frontier in machine learning by interpreting biological sequence data, including DNA, RNA, and proteins.

genXtraits Inc. has announced that it has entered into an agreement with Pairwise to deploy its Fulcrum editing tools to ...

This study presents important findings on cold tolerance shared between hibernating and non-hibernating mammals, identifying a key molecule, GPX4, through multi-species genome-wide CRISPR screens. The ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...